GLP-1 weight-loss drug, whose full name is Glucagon-like peptide-1 receptor agonist. Initially, GLP-1 was a hormone secreted by the gastrointestinal tract mainly used for treating diabetes, but it has also been used to suppress appetite and control weight.
- 1857.242
- -22.257-1.18%
Viking Stock Climbs 11% Post-market on Obesity Drug Update
Viking Therapeutics Stock Climbs On Q2 EPS Beat
Expert Outlook: Eli Lilly and Co Through The Eyes Of 25 Analysts
Eli Lilly and Co Analyst Ratings
UK's NHS Prescribes Weight-Loss Drug Wegovy Less Than Expected Due To Service Shortages
Pfizer/ BioNTech Win U.K. Nod for JN.1-adjusted COVID-19 Shot
Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study
Pfizer/ Sangamo Gene Therapy for Hemophilia A Succeeds in Late-stage Trial
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
Notable Earnings After Wednesday's Close
Viking Therapeutics Q2 2024 Earnings Preview
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
10 Health Care Stocks Whale Activity In Today's Session
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $6,600 Today
Viiv's Dovato as Effective as Gilead' Biktarvy for HIV but With Less Weight Gain
Election Watch: Will Conservatives and Liberals Move the Meter With Their Stock Picks?
Amgen, Garmin Among Relative Market Leaders Poised to Outperform in Coming Months: BTIG
Market Whales and Their Recent Bets on LLY Options
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst